Search results
Added:
3 years ago
Leaflet motion abnormalities (LMAs) are a relatively new entity in the field of transcatheter aortic valves (TAVs).1–4 They can be associated with the thrombosis of the bioprosthesis (TAVT), often leading to dramatic clinical scenarios1 or, on the other hand, they can result in a hypoattenuated leaflet thickening (HALT) and/or reduced leaflet motion (RELM), both usually associated with gradients…
View more
Start date:
Jan 16, 2018
View more
Added:
3 years ago
Transcatheter aortic valve implantation (TAVI) is now the accepted treatment option of choice for patients presenting with severe symptomatic aortic stenosis who are deemed to be inoperable or of high surgical risk.1,2 Short- and intermediate-term outcomes have been promising3–5 and with increasing institutional and operator experience combined with technological advancements there has been…
View more
Added:
3 years ago
Transcatheter aortic valve implantation (TAVI) has undoubtedly revolutionised the treatment of severe aortic stenosis and has become the preferred treatment option for patients at increased surgical risk.1,2 Although outcomes have improved and complications reduced over time, certain potentially catastrophic complications remain.3,4 Coronary obstruction has long been a feared complication and is…
View more
Added:
3 years ago
Aortic stenosis (AS) is one of the most common valvular diseases in developed countries and its prevalence is projected to increase over the next decade as the population ages.1,2 Transcatheter aortic valve implantation (TAVI) is an established alternative to surgery for treatment of patients with symptomatic, severe AS.3
As the latest multicentre trials have established the role of TAVI…
View more
Added:
3 years ago
Among patients undergoing surgical valve replacement, 1–5 % of patients with an aortic valve replacement (AVR) and 2–12 % with a mitral valve replacement (MVR) may develop paravalvular regurgitation or ‘leak’ (PVL).1–3 In the era of transcatheter aortic valve replacement (TAVR) with first-generation balloon expandable valves, up to 17 % of patients may be left with moderate or severe PVL, also…
View more
Added:
3 years ago
Over the past 30 years, several percutaneous transcatheter technologies and devices for interventions in structural heart diseases (SHDs) have been introduced (see Table 1). There are numerous technologies that are in development or are currently being used to treat patients with SHD that use transcatheter techniques. The variety of percutaneous treatment approaches has led to a revolution and…
View more
Added:
1 year ago
Added:
3 years ago
Reconstructive valve surgery encompasses a comprehensive system of valve analysis and related techniques based on three basic principles as described by Alain Carpentier and colleagues: restoring or preserving the full mobility of the leaflets, creating a large surface of leaflet coaptation and remodelling the annulus to provide an optimal and stable orifice area.1 Mitral valve regurgitation (MR)…
View more
Added:
1 year ago
